News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
New role strengthens Quantori’s global leadership position in data science & digital IT
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
The covid health center will be managed and administered by the district administration of Ballari
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Subscribe To Our Newsletter & Stay Updated
